An introduction to the concept of "quality of life in Parkinson's disease"

被引:112
作者
Martinez-Martin, P [1 ]
机构
[1] Univ Hosp Getafe, Dept Neurol, E-28905 Getafe, Spain
关键词
quality of life; Parkinson's disease; assessment; questionnaires; cost-effectiveness;
D O I
10.1007/PL00007733
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The sense of well-being is central to the concept of quality of life (QoL), but there is not a universally accepted definition of health-related QoL. QoL refers to the patient's own evaluation of the impact of the disease. It includes physical, psychological and socioeconomic dimensions, and its measurement is of paramount importance in evaluating research outcomes and in cost-benefit analyses. In addition, QoL assessment helps to identify problems and may be essential in chronic and disabling diseases such as in Parkinson's disease (PD). There are numerous reasons for the decrease in QoL suffered by PD patients: restrictions in mobility. falls, emotional disorders, social embarrassment, isolation, sleep disturbances, dyskinesias, and fluctuations. Many aspects of these disorders go unnoticed in clinical evaluation, and only QoL assessment allows them to be rated. Generic instruments have been used in a few studies measuring QoL in PD patients. Only recently have specific instruments as PDQ-39 and PDQL-37 been designed and validated. QoL assessment in PD is an important and expanding area, with a promising application in clinical trials and pharmacoeconomics.
引用
收藏
页码:S2 / S6
页数:5
相关论文
共 27 条
[1]  
[Anonymous], HDB BAS DOC
[2]  
[Anonymous], QUALITY LIFE PHARMAC
[3]   Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study [J].
Baron, MS ;
Vitek, JL ;
Bakay, RAE ;
Green, J ;
Kaneoke, Y ;
Hashimoto, T ;
Turner, RS ;
Woodard, JL ;
Cole, SA ;
McDonald, WM ;
Delong, MR .
ANNALS OF NEUROLOGY, 1996, 40 (03) :355-366
[4]   SICKNESS IMPACT PROFILE - VALIDATION OF A HEALTH STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
POLLARD, WE ;
MARTIN, DP ;
GILSON, BS .
MEDICAL CARE, 1976, 14 (01) :57-67
[5]   Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study [J].
Block, G ;
Liss, C ;
Reines, S ;
Irr, J ;
Nibbelink, D ;
Aarli, J ;
Aguilar, M ;
Ahrens, S ;
Bakheit, A ;
Baumel, B ;
Bertoni, J ;
Capildeo, R ;
CastroCaldas, A ;
Deza, L ;
Donaldson, I ;
Franck, G ;
Fusillo, J ;
Gauthier, S ;
Gershanik, O ;
Granerus, AK ;
Hauser, RA ;
Hennessey, K ;
Hutton, JT ;
Joffe, R ;
Koller, W ;
Last, B ;
LeWitt, P ;
Mamoli, B ;
Manyam, B ;
Mark, M ;
Nakano, K ;
Nausieda, P ;
Otero, E ;
Paulson, G ;
Pinter, M ;
Reich, S ;
Rodnitzky, R ;
Sage, J ;
Sampaio, C ;
Smith, B ;
Teravainen, H ;
Tetrud, J ;
Tolosa, E ;
Ulm, G ;
Valesco, F .
EUROPEAN NEUROLOGY, 1997, 37 (01) :23-27
[6]   Quality of life in patients with Parkinson's disease: Development of a questionnaire [J].
deBoer, AGEM ;
Wijker, W ;
Speelman, JD ;
deHaes, JCJM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :70-74
[7]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[8]  
FITZSIMMONS B, 1993, NURS CLIN N AM, V28, P807
[9]  
GLOZMAN JM, 1997, MOV DISORD S1, V12, P48
[10]   QUALITY-OF-LIFE ASSESSMENT IN CANCER-TREATMENT PROTOCOLS - RESEARCH ISSUES IN PROTOCOL DEVELOPMENT [J].
GOTAY, CC ;
KORN, EL ;
MCCABE, MS ;
MOORE, TD ;
CHESON, BD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (08) :575-579